Case Report
Early-Onset Alzheimers Disease Diagnosis and Treatment Challenges: A 57-Year-Old Male Case Report
Tara D Sharma, Ravi Kumar Sharma* and Sudhir Sharma
Corresponding Author: Ravi Kumar Sharma, Department of Biotechnology, University Institute of Biotechnology, Chandigarh University, Mohali Punjab 140413, India.
Received: February 10, 2025; Revised: February 19, 2025; Accepted: February 22, 2025 Available Online: March 20, 2025
Citation: Sharma TD, Sharma RK & Sharma S. (2025) Early-Onset Alzheimers Disease Diagnosis and Treatment Challenges: A 57-Year-Old Male Case Report. BioMed Res J, 9(1): 834-836.
Copyrights: ©2025 Sharma TD, Sharma RK & Sharma S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share :
  • 66

    Views & Citations
  • 10

    Likes & Shares
We herewith report of Alzheimer disease (AD)57 years old male patient with a history of memory loss, word reputation, and notable changes in his capacity to carry out everyday duties, such as handling money and planning tasks at home. And the results showed the all three interleukins-6 (IL-6), tumor necrosis factor-α(TNF-α), and interleukins-1β (IL-1β) are associated with AD.

Keywords: EOAD, Alzheimer disease, IL-1β, IL-6, TNFα
INTRODUCTION

AD is a neurological ailment that cause progressive cognitive loss [1]. AD has emerged as a significant public health concern. It is the main cause of dementia. The illness known as dementia is linked to persistent, gradual brain deterioration which is accounting for approximately 60 to 80% [2,3]. Dementia causes steady decline in memory, cognition, behavior, and social skills, reducing overall functionality. Memory impairment and psychobehavioral disorders are the main clinical signs of this condition, which affects older individuals over 65 years old [4]. According to 2013 report pathological changes in AD start 15 years before clinical symptoms appear and irreversible damage to the brain system has occurred previously by the time of diagnosis [5].

AD has been classified into two categories: early onset Alzheimer’s disease (EOAD) and late onset Alzheimer’s disease (LOAD). AD that appears before the age of 65 is known as EOAD [6,7] 5 to 10 % of AD cases are EOAD cases, although 10-15 % of these cases have recognized mutations in the APP (Amyloid precursor protein), PSEN1, and PSEN2, which are associated with EOAD [8].

Previous studies have reported Alcohol is significance as a risk factor and contribution to AD related cognitive deterioration [9]. It has been reported that Cigarettes' nicotine and other chemicals can harm blood vessels, reducing blood flow to the brain and impairing its ability to operate. Conditions like Alzheimer's may arise as a result of this. Furthermore, smoking increases oxidative stress and inflammation [10]. Recently a case control study is being done on 59-year-old woman was diagnosed with depression at the age of 50 At the age of 53, she began to exhibit cognitive dysfunction, which included memory loss and disorientation, and she eventually developed dementia [11].

CASE REPORT

A 57-Year-old male patient, weight-70 Kg, BP 81/118 resident of rural Kullu, the patient came to OPD of Neurology department, IGMC& Hospital Shimla Himachal Pradesh with 12-month history of memory loss, trouble pronouncing words, and notable changes in his capacity to carry out everyday duties, such as handling money and planning tasks at home. He was also observed to be more socially isolated and irritable. On neurological examination by the physicians, the patient was found to have cerebellar atrophy, MMSE score was 16/30, blurring of vision, the patient came with the history of depression from last 2 years no hypertension, no head injury. Patient was use to tobacco, opium the patient was alcoholic, non- vegetarian patients was married at 17 years of his age with 2 kids. patient was prescribed on Memantine hydrochloride and Donepezil hydrochloride 5 mg & also on multivitamins.

Hemoglobin level, fasting blood sugar, serum urea, creatinine, SGOT, SGPT, ALP, TSH, uric acid cholesterol, Vit D, Vit B12, Cal, Hba1c level. 14.7g, 97 mg/dl%, 13mg%, 0.7mg%, 31 IU/L, 20 IU/L, 50 IU/L,3.5 mg/dl,6.5 mg/dl, 108 mg/dl, 113 IU, 20 (pg/ml) 9.1 mg/dl, HbA1c reported 5.0% respectively. We performed sandwich ELISA of IL-6, IL-1β & TNF-α on Thermofisher Scientific ELISA.

MRI report shows multiple punctate signal intensity are seen in bilateral frontoparietal subcortical white matter showing hyper intense signal on T2W and FLAIR images suggestive of chronic microangiopathic changes, bilateral ventricle and sulci are prominent-suggestive of cerebral atrophy.

RESULT

The result of this study demonstrated that all three interleukins were elevated and Vit B12 & vit D reported deficient in this case report patient.

DISCUSSION

In this case report we found levels of IL-6, TNF, and IL-1β elevated in patients with EOAD and their possible contribution to the illness according to our findings, EOAD patients had noticeably higher levels of these pro-inflammatory cytokines than age-matched controls. Our study was similar to Dursun E [11] found IL-6 & IL 1β elevated in EOAD patient’s serum. Our research indicates that these cytokines are essential for amplifying neurodegeneration and accelerating the course of EOAD. Targeting these cytokines with particular inhibitors may provide novel therapeutic options for controlling EOAD, and clinically, they may function as biomarkers for early diagnosis and disease monitoring. These findings are compared with previous research they also found that IL-1β values were higher in people with AD, Chen R [12] and KIM YS [13] also found elevated TNFα in AD patients. [12,13].

CONCLUSION

In conclusion, this case highlights the difficulties in identifying and treating a 62-year-old woman with early-onset Alzheimer's disease. To confirm Alzheimer's disease, clinicians must use extensive diagnostic techniques and consider a wide range of differential diagnoses. Improving the quality of life for patients and their families requires a customized management strategy that incorporates cognitive, psychosocial, and pharmacologic interventions. For early-onset Alzheimer's, more research is required to improve diagnostic standards and investigate novel treatment approaches.
  1. Santiago JA, Potashkin JA (2021) The impact of disease comorbidities in Alzheimer's disease. Front Aging Neurosci 13: 631770.
  2. Fatima A, Dash PJ, Gupta S, Khan S (2024) Physiotherapy for Alzheimer’s Disease: A Case Report. Interdiscipl Rehab 4: 83.
  3. Chin JH, Vora N (2014) The global burden of neurologic diseases. Neurology 83(4): 349-351.
  4. Zhao QF, Tan L, Wang HF, Jiang T, Tan MS, et al. (2016) The prevalence of neuropsychiatric symptoms in Alzheimer's disease: Systematic review and meta-analysis. J Affect Disord 190: 264-271.
  5. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, et al. (2013) The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement 9(5): e111-e194.
  6. Ayodele T, Rogaeva E, Kurup JT, Beecham G, Reitz C (2021) Early-onset Alzheimer’s disease: What is missing in research? Curr Neurol Neurosci Rep 21(2): 4.
  7. Reitz C, Rogaeva E, Beecham GW (2020) Late-onset vs nonmendelian early-onset Alzheimer disease: A distinction without a difference? Neurol Genet 6(5): e512.
  8. Venkataraman A, Kalk N, Sewell G, Ritchie CW, Lingford-Hughes A (2017) Alcohol and Alzheimer's disease-does alcohol dependence contribute to beta-amyloid deposition, neuroinflammation and neurodegeneration in Alzheimer's disease? Alcohol Alcohol 52(2): 151-158.
  9. Yamada H, Yamazaki Y, Takebayashi Y, Yazawa K, Sasanishi M, et al. (2024) The long-term effects of heated tobacco product exposure on the central nervous system in a mouse model of prodromal Alzheimer's disease. Sci Rep 14(1): 227.
  10. Liu M, Xie X, Xie J, Tian S, Du X, et al. (2023) Early-onset Alzheimer’s disease with depression as the first symptom: A case report with literature review. Front Psychiatry 14: 1192562.
  11. Dursun E, Gezen-Ak D, Hanağası H, Bilgiç B, Lohmann E (2015) The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer's disease, mild cognitive impairment or Parkinson's disease. J Neuroimmunol 283: 50-57.
  12. Chen R, Yin Y, Zhao Z, Huang L, Huang S, et al. (2012) Elevation of serum TNF-α levels in mild and moderate Alzheimer patients with daytime sleepiness. J Neuroimmunol 244(1-2): 97-102.
  13. Kim YS, Lee KJ, Kim H (2017) Serum tumor necrosis factor‐α and interleukin‐6 levels in Alzheimer's disease and mild cognitive impairment. Psychogeriatric 17(4): 224-230.